Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
EditorialEditorial

Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle

Xiubao Ren
Cancer Biology & Medicine May 2019, 16 (2) 205-210; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0141
Xiubao Ren
1Department of Biotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rwziyi{at}yahoo.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 16 no. 2 205-210
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2018.0141

Published By 
Cancer Biology & Medicine
History 
  • Received April 16, 2019
  • Accepted May 10, 2019
  • Published online May 1, 2019.

Copyright & Usage 
Copyright: © 2019, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

Cited By...

  • 31 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 16 (2)
Cancer Biology & Medicine
Vol. 16, Issue 2
1 May 2019
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
Xiubao Ren
Cancer Biology & Medicine May 2019, 16 (2) 205-210; DOI: 10.20892/j.issn.2095-3941.2018.0141

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
Xiubao Ren
Cancer Biology & Medicine May 2019, 16 (2) 205-210; DOI: 10.20892/j.issn.2095-3941.2018.0141
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Cancer immunotherapy: from enhancement to normalization
    • TCAA: a new member in the arsenal of tumor basic and translational research
    • Discovery of the novel Siglec-15 immune suppressor and its vital role as an immune normalization target
    • Perspective
    • Conflict of interest statement
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Screening and Identification of a Novel Anti-Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity
  • Exhausted T cells and epigenetic status
  • Google Scholar

More in this TOC Section

  • Multi-cancer early detection: from promise to practice and the next frontier
  • Tumor microenvironment-responsive polymeric nanoparticles for enhanced immunotherapy
  • Harnessing the STING pathway for HCC treatment
Show more Editorial

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire